Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGB3 | P05106 | 20/20 | 0.81 |
| ▸ | ITGAV | P06756 | 17/20 | 0.81 |
| ▸ | ITGA2B | P08514 | 17/20 | 0.81 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7402257 | 0.90 | ITGB3 (1.00) | ITGB3ITGAVITGA2B | |
| SCHEMBL7405151 | 0.89 | ITGB3 (0.92) | ITGB3ITGAVITGA2B | |
| Trifluoroacetic Acid SCHEMBL7403079 | 0.87 | ITGB3 (0.91) | ITGB3ITGAVITGA2B | |
| SCHEMBL7403221 | 0.83 | ITGB3 (1.00) | ITGB3ITGAVITGA2B | |
| SCHEMBL7400624 | 0.82 | ITGB3 (0.82) | ITGB3ITGAVITGA2B | |
| SCHEMBL8552846 | 0.82 | ITGB3 (0.82) | ITGB3ITGAVITGA2B | |
| SCHEMBL7398015 | 0.81 | ITGB3 (1.00) | ITGB3ITGAVITGA2B | |
| SCHEMBL7982983 | 0.78 | ITGB3 (0.74) | ITGB3ITGAVITGA2B | |
| SCHEMBL7404633 | 0.77 | ITGB3 (1.00) | ITGB3ITGAVITGA2B | |
| SCHEMBL7403929 | 0.77 | ITGB3 (1.00) | ITGB3ITGAVITGA2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120003229-A1 | MODULATORS OF CYTOKINE MEDIATED SIGNALLING PATHWAYS AND INTEGRIN ALPHAVBETA3 RECEPTOR ANTAGONISTS FOR COMBINATION THERAPY | GENESTE HERVE (DE) | 2012-01-05 | — | — | US | disclosed |
| US-20090311266-A1 | Inhibitors of the endothelin signalling pathway and alphavbeta3 integrin receptor antagonists for combination therapy | BASF AKTIENGESELLSCHAFT (DE) | 2009-12-17 | — | — | US | disclosed |
| EP-1239877-B1 | COMPOSITION COMPRISING A TNF-ALPHA INHIBITOR AND AN INTEGRIN ALPHAVBETA3 RECEPTOR ANTAGONIST | ABBOTT GMBH & CO KG (DE) | 2008-01-09 | — | — | EP | disclosed |
| US-20060159678-A1 | Modulators of cytokine mediated signaling pathways and integrin alphabeta3 receptor antagonists for combination therapy | GENESTE HERVE | 2006-07-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060159678-A1 | Modulators of cytokine mediated signaling pathways and integrin alphabeta3 receptor antagonists for combination therapy | ITGB3, IL6ST, IL1RN | ITGB3 1/4885ITGAV 11/4885ITGA2B 10/4885 |
| US-20090311266-A1 | Inhibitors of the endothelin signalling pathway and alphavbeta3 integrin receptor antagonists for combination therapy | EDNRB, EDNRA, ITGB3 | ITGB3 3/4885ITGAV 4/4885ITGA2B 12/4885 |
| US-20120003229-A1 | MODULATORS OF CYTOKINE MEDIATED SIGNALLING PATHWAYS AND INTEGRIN ALPHAVBETA3 RECEPTOR ANTAGONISTS FOR COMBINATION THERAPY | ITGB3, ITGAV, ITGB1 | ITGB3 1/4885ITGAV 2/4885ITGA2B 9/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.